Company / Capital Expenditures
Apellis Pharmaceuticals, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$313.0K
FY2025
5-year range
$313.0K / $1.5M
FY2021-FY2025
Trend
-22.3%
vs FY2024
Sector context
#150 of 194
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s capital expenditures of $313,000 is lower than 77% of companies in the Health Care sector (FY2025). Capital Expenditures has declined for 3 consecutive years, from $2M in FY2022 to $313,000 in FY2025.
Based on SEC 10-K filings.
$313,000 in FY2025 with a 5-year CAGR of -43.5%.
Declined from $773,000 to $313,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -41.0%
- 5-Year CAGR
- -43.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 194This company $313.0K Sector average $117.5M
▼
-99.7% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -43.5%, indicating a declining trend.
- In FY2025, capital expenditures decreased 22.3% year-over-year.
- Ranks #150 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $313.0K | -22.3% |
| FY2024 | $403.0K | -47.9% |
| FY2023 | $773.0K | -49.3% |
| FY2022 | $1.5M | +38.2% |
| FY2021 | $1.1M | -79.7% |
| FY2020 | $5.4M | +220.3% |
| FY2019 | $1.7M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026